NASDAQ:AEZS - Aeterna Zentaris Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.98
▲ +0.0207 (2.15%)
1 month | 3 months | 12 months
Get New Aeterna Zentaris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AEZS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AEZS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aeterna Zentaris in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.98.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Aeterna Zentaris. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2019HC WainwrightReiterated RatingBuyLow
i
1/17/2019HC WainwrightReiterated RatingBuyLow
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/20/2018Maxim GroupSet Price TargetBuy$2.00Low
i
Rating by Jason Kolbert at Maxim Group
12/20/2018HC WainwrightSet Price TargetBuy$3.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/14/2018HC WainwrightReiterated RatingBuy$3.00Low
i
6/15/2018Maxim GroupReiterated RatingBuyLow
i
Rating by Jason McCarthy at Maxim Group
5/9/2018HC WainwrightReiterated RatingBuy$3.00High
i
Rating by S. Ramakanth at HC Wainwright
3/29/2018HC WainwrightReiterated RatingBuy$3.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/28/2018Maxim GroupSet Price TargetBuy$4.00Medium
i
Rating by Jason McCarthy at Maxim Group
1/17/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Jason Kolbert at Maxim Group
12/21/2017Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Jason Kolbert at Maxim Group
11/29/2017HC WainwrightSet Price TargetBuy$3.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/28/2017Maxim GroupSet Price TargetBuy$4.00Low
i
Rating by Jason Kolbert at Maxim Group
8/11/2017Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Jason Kolbert at Maxim Group
7/19/2017Maxim GroupBoost Price TargetBuy ➝ Buy$2.00 ➝ $4.00High
i
Rating by Jason Kolbert at Maxim Group
7/5/2017HC WainwrightSet Price TargetBuy$3.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/1/2017Maxim GroupSet Price TargetBuy$2.00Low
i
Rating by Jason Kolbert at Maxim Group
5/10/2017HC WainwrightLower Price TargetBuy ➝ Buy$7.50 ➝ $3.00Low
i
5/1/2017Maxim GroupSet Price TargetBuy ➝ Buy$11.00 ➝ $2.00High
i
Rating by Jason Kolbert at Maxim Group
3/30/2017Maxim GroupReiterated RatingBuy$11.00High
i
Rating by Jason Kolbert at Maxim Group
3/16/2017Maxim GroupSet Price TargetBuy$10.00 ➝ $11.00Low
i
Rating by Jason Kolbert at Maxim Group
3/8/2017Maxim GroupReiterated RatingBuy$6.00Low
i
Rating by Jason Kolbert at Maxim Group
2/14/2017Maxim GroupSet Price TargetBuy$10.00N/A
i
Rating by Jason Kolbert at Maxim Group
2/1/2017Maxim GroupSet Price TargetBuy$10.00N/A
i
1/17/2017Maxim GroupBoost Price TargetBuy$7.00 ➝ $10.00N/A
i
1/10/2017HC WainwrightReiterated RatingBuy$12.00 ➝ $7.50N/A
i
1/8/2017Canaccord GenuitySet Price TargetBuy$7.50 ➝ $6.00N/A
i
Rating by Neil Maruoka at Canaccord Genuity
11/20/2016HC WainwrightReiterated RatingBuy$12.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/11/2016Canaccord GenuityReiterated RatingBuy$9.00 ➝ $7.50N/A
i
11/10/2016Maxim GroupReiterated RatingBuy$11.00 ➝ $10.00N/A
i
Rating by Jason Kolbert at Maxim Group
8/23/2016Canaccord GenuityReiterated RatingBuy$9.00N/A
i
8/13/2016Maxim GroupReiterated RatingBuy$11.00N/A
i
Rating by Jason Kolbert at Maxim Group
8/11/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/2/2016Maxim GroupReiterated RatingBuy$11.00N/A
i
Rating by Jason Kolbert at Maxim Group
7/10/2016HC WainwrightReiterated RatingBuy$12.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/5/2016Maxim GroupReiterated RatingBuy$11.00N/A
i
Rating by Jason Kolbert at Maxim Group
6/15/2016Maxim GroupReiterated RatingBuy$11.00N/A
i
Rating by Jason Kolbert at Maxim Group
5/10/2016Maxim GroupReiterated RatingBuy$11.00N/A
i
Rating by Jason Kolbert at Maxim Group
5/2/2016Maxim GroupReiterated RatingBuy$11.00N/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 4/14/2016 forward)
Aeterna Zentaris logo
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Read More

Today's Range

Now: $0.98
$0.97
$0.99

50 Day Range

MA: $1.15
$0.92
$1.51

52 Week Range

Now: $0.98
$0.29
$3.62

Volume

10,487 shs

Average Volume

19,095,268 shs

Market Capitalization

$61.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Aeterna Zentaris?

The following Wall Street analysts have issued stock ratings on Aeterna Zentaris in the last year:
View the latest analyst ratings for AEZS.

What is the current price target for Aeterna Zentaris?

0 Wall Street analysts have set twelve-month price targets for Aeterna Zentaris in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aeterna Zentaris in the next year.
View the latest price targets for AEZS.

What is the current consensus analyst rating for Aeterna Zentaris?

Aeterna Zentaris currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AEZS.

What other companies compete with Aeterna Zentaris?

How do I contact Aeterna Zentaris' investor relations team?

Aeterna Zentaris' physical mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company's listed phone number is 49-6942-6020 and its investor relations email address is [email protected] The official website for Aeterna Zentaris is www.zentaris.com.